Novonesis stock continues buyback program as OMXC25 weight adds support
Published on 09/19/2026 at 13:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novonesis stock (ISIN DK0060336014) closed at DKK 435.90 on Nasdaq Copenhagen on September 8, 2026, with the shares trading in a tight range as the company continued a structured B share buyback program based on recent closing prices.
Buyback tranche underpins Novonesis shares
According to Ad-hoc-news on September 18, 2026, Novonesis has structured a first tranche of its B share buyback program with reference to the closing share price on September 11, 2026, corresponding to around 1.3 million B shares. The same overview notes that the stock last recorded a closing price of DKK 435.90 on Nasdaq Copenhagen on September 8, 2026, with a reported volume of 397,728 shares and no percent change versus the prior day, reflecting a period of consolidation after earlier strength.
The movement from DKK 450.60 on September 3, 2026 to DKK 435.90 on September 8, 2026 represents a decline of about 3.3 percent over those sessions, indicating that the buyback is being executed against slightly softer prices than the early September peak, which can increase the number of shares retired for a given cash amount. Per the same data, the technical picture is described as neutral, with a separate price indication around DKK 426.80 on September 17, 2026 compared with a reference level of DKK 442.17, meaning the stock was trading below that comparative value and suggesting moderate short-term pressure.
Index weight and fundamentals frame valuation
Novonesis is one of the larger constituents in the OMX Copenhagen 25 Index, which stood at 1,870.16 points as of September 18, 2026, down 0.68 percent from the prior close according to Nasdaq OMX. This index role means that flows from domestic and international index and ETF investors add a structural demand component for Novonesis stock, even when short-term trading is subdued.
On the fundamental side, a recent private-comps overview compiled by Multiples.vc lists Novonesis as a publicly listed company headquartered in Denmark with revenue of USD 4.8 billion and EBITDA of USD 1.6 billion, set against a valuation of USD 31 billion. These figures imply an EBITDA margin of roughly 33.3 percent for the most recently assessed fiscal period, underlining the profitability of its enzyme and microbial solutions portfolio, and a revenue multiple of 6.7 times, which positions the stock in a premium bracket relative to many traditional industrial names.
The same source explains that Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen, creating a global leader in industrial enzymes and microbial solutions with close to 50 percent market share in both categories. The company supplies biological solutions to sectors ranging from household care and food and beverages to bioenergy, agriculture and feed, technical applications and pharmaceuticals, helping customers improve yield, efficiency and performance while saving energy and reducing waste. With more than 11,000 employees, over 30 research and application centers and 23 manufacturing sites worldwide, the operational footprint is substantial, which supports the argument that the current valuation reflects not only near-term earnings but also strategic positioning in high-growth sustainability-oriented markets.
Stock trades below early-September levels
For investors, the recent price action offers a concrete reference frame. From the early September closing level of DKK 450.60 to the later closing price of DKK 435.90, the roughly 3.3 percent pullback has brought Novonesis stock below its short-term peak, while the neutral technical signal around a mid-September price near DKK 426.80 versus a reference level of DKK 442.17 suggests the shares are currently trading under that comparative benchmark, which can be seen as a modest discount relative to very recent history. With the OMXC25 index itself down 0.68 percent as of September 18, 2026, part of the move can be attributed to broader Danish large-cap market dynamics rather than company-specific news alone.
As the B share buyback tranche of about 1.3 million shares proceeds, the reduction in free float shares may gradually support earnings per share metrics and could help offset index-related volatility. Given the company’s multi-billion revenue base and double-digit EBITDA margin profile, the interplay between buyback activity, index flows and sector demand for biological solutions is likely to remain a key narrative for Novonesis stock in the coming quarters.
Novonesis stock price and trading venue
Novonesis B shares are listed on Nasdaq Copenhagen, where they closed at DKK 435.90 on September 8, 2026, with a reported trading volume of 397,728 shares and a daily change of 0.00 percent versus the prior day. This closing level, together with the decline from DKK 450.60 earlier in the month and the neutral technical readings around DKK 426.80 compared with a reference price of DKK 442.17, frames the current market context for the stock on its primary Danish exchange.
Key data on Novonesis stock
- Company: Novonesis A/S
- ISIN: DK0060336014
- Ticker: NOVO B
- Trading venue: Nasdaq Copenhagen
- Price (as of September 8, 2026): 435.90 DKK
- Market capitalization: 31,000,000,000 USD (as of September 19, 2026)
- Sector / Industry: Biotechnology / Industrial enzymes and microbial solutions
- Index membership: OMX Copenhagen 25 Index (OMXC25)
